One Pager as on June 30, 2025
![]() | Potential growth tailwinds in Indian Economy. |
![]() | Opportunity to capitalize on Indian Entrepreneurship. |
![]() | Opportunity to capture market / economic cycles. |
![]() | Potential to create wealth and generate alpha over long-term. |
![]() | Small caps are generally under-researched and under-owned and hence provides an opportunity for stock-picking at reasonable valuations. |
![]() | Small Caps could be beneficiaries of structural reforms announced from time to time. |
![]() | Small caps also provide exposure to companies which are potential market leaders in the industries they operate in (a few examples include textile, paper, sugar, luggage) and have potential to become midcaps of tomorrow as they achieve scale. |
Security | % to Net Assets |
APL Apollo Tubes Limited | 3.18% |
Bajaj Auto Limited | 2.68% |
Aditya Birla Real Estate Limited | 2.51% |
Central Depository Services (India) Limited | 2.31% |
RBL Bank Limited | 2.26% |
The Ramco Cements Limited | 2.18% |
eClerx Services Limited | 2.17% |
Firstsource Solutions Limited | 2.10% |
Godfrey Phillips India Limited | 2.09% |
PNB Housing Finance Limited | 2.09% |
Total | 23.56% |
Sector | MMSCF* | BSE 250 Small Cap TRI |
Financial Services | 19.67% | 20.27% |
Capital Goods | 17.88% | 14.29% |
Automobile And Auto Components | 9.56% | 4.92% |
Fast Moving Consumer Goods | 8.37% | 4.98% |
Healthcare | 6.81% | 13.09% |
*Mahindra Manulife Small Cap Fund
Data as on June 30, 2025
Turnover Ratio (Last 1 year) | 1.03 |
Fresh Additions | Complete Exits |
Security | Security |
Belrise Industries Ltd. | Bharat Bijlee Limited |
Glenmark Pharmaceuticals Limited | Emami Limited |
NHPC Limited | Kotak Mahindra Bank Limited |
Oswal Pumps Limited | Lupin Limited |
- | NLC India Limited |
- | Piramal Pharma Limited |
- | Tata Communications Limited |
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant
portfolio changes during the month and should not be construed as recommendation to buy/sell/
hold. The fund manager may or may not choose to hold these companies/stocks, from time to
time. Investors are requested to consult their financial, tax and other advisors before taking any
investment decision(s). Data as on June 30, 2025
^Benchmark ^^Additional Benchmark. Inception/Allotment date: 12-Dec-22.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. *Based on standard investment of Rs. 10,000 made at the beginning of the relevant period. Mr. Krishna Sanghavi is managing this fund since October 24, 2024. Mr. Vishal Jajoo is managing this fund since December 23, 2024.
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 12-Dec-22.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Krishna Sanghavi manages 6 schemes, Mr. Manish Lodha manages 10 schemes and Mr. Vishal Jajoo manages 3 scheme each of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
Performance as on June 30, 2025
This product is suitable for investors who are seeking*:
• Long term capital appreciation;
• Investment predominantly in equity and equity related securities of small cap companies.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.